RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - COMPLICANZE OSTETRICHE DA ANTICORPI ANTI-FOSFOLIPIDI: meccanismi patogenetici molecolari quali nuovi target terapeutici e marcatori prognostici.
• 2 - Medulloblastoma: studio delle vie molecolari di sviluppo e progressione tumorale allo scopo di identificare approcci terapeutici innovativi
• 3 - Ruolo di TRAIL nella fisiopatologia emopoietica e vascolare
• 4 - Nuove conoscenze fisiopatologiche per nuove prospettive terapeutiche del colangiocarcinoma
• 5 - Un modello pre-clinico di terapia antitumorale e rigenerazione ossea con cellule staminali mesenchimali geneticamente modificate
• 6 - Patogenesi molecolare ed analisi sequenziale di interazioni cellulari e marcatori biologici di progressione di malattia e di resistenza al trattamento nella leucemia linfatica cronica
• 7 - Terapia cellulare in utero per la cura dell'Osteogenesis Imperfecta utilizzando il modello murino Knock-in per l'OI BrtlIV.
• 8 - Cellule Staminali Cardiache Umane e loro potenziale rigenerativo
• 9 - Ruolo dei microRNA nel differenziamento cellulare e nella tumorigenesi
• 10 - Progettazione, sintesi, caratterizzazione e sviluppo di nuovi inibitori delle deacetilasi istoniche con potenziali attività traslazionali per il trattamento delle leucemie mieloidi acute

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze biologiche
  • BIOCHIMICA
  • BIOLOGIA APPLICATA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)

Classificazione geografica

• Regione: Emilia Romagna

Bibliografia

1.Bonnet D and Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730,1997.
2.Grimwade D and Enver T. Acute promyelocytic leukemia: where does it stem from? leukemia 18:375,2004
3.Hope KJ, et al. Human acute myeloid leukemia stem cells. Arch Med Res 34:507,2003.
4.Blair A, et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo.Blood 89:3104,1997.
5.Jordan CT, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14:1777,2000.
6.Hope KJ, et al (2004) Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 7, 738
7.Guenechea G, Gan OI, Dorrell C, Dick JE. Distinct classes of human stem cells that differ in proliferative and self-renewal potential.Nat Immunol. 2001 Jan;2(1):75-82.
8.Lapidot T, et al. How do stem cells find their way home? Blood. 2005;105:1901-1910.
9.Spiegel A, et al. Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signalling.Blood.2004;103(8):2900-7.
10.Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV entry. Nature. 1996;382:829-832.
11.Peled A et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999;283: 845-848.
12.Bradstock KF, et al.Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers. Leukemia. 2000;14: 882-888.
13.Legras S. et al. A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia.Blood 91: 3401,1998.
14.Charrad RS. et al. Ligation of the CD44 adhesion molecule reverses blockage of differentiation of acute meloid leukemia.Nat.Med. 6:669, 1999.
15.Charrad RS. et al. Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood 99: 290,2002.
16.Candido EPM. et al. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 14:105, 1978.
17.Coradini D. et al. Hyaluronic acid butyric esters as promising antineoplastic agents in human lung carcinoma: a preclinical study. Invest New Drugs 22:207, 2004.
18.Bullinger L, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med.2004,350(16):1605-16.
19.Valk PJ, et al.Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004,350(16):1617-28.
20.Tagliafico E, et al. Gene expression profile of Vitamin D3 treated HL60 cells shows an incomplete molecular phenotypic conversion to monocytes. Cell Death Differ. 2002,9(11):1185-95.
21.Tagliafico E., et al.Identification of a molecular signature predictive of refractoriness in Acute Myeloid Leukemia, Leukemia, in press.
22.Manfredini R, et al..The kinetic status of Hemopoietic Stem Cell (HSC) subpopulations underlies a differential expression of genes involved in self-renewal, commitment and engraftment". Stem Cells, 2005,23(4):496-506.
23.Lemoli RM, et al. Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34- human stem cells. Br J Haematol.2003 Nov;123(4):720-9.
24.Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001,107(7):823-6.
25.Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science. 2002,297(5589):2056-60.
26.Xu P, et al. The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Curr Biol. 2003,13(9):790-5.
27:Fazi F, et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell. 2005,123(5):819-31.
28.Chen CZ, et al. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004,303(5654):83-6.
29.Calin GA, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005, 353(17):1793-801.
30.Cimmino A, et al.miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005,102(39):13944-9.
31.Lemoli RM, et al. Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. Blood. 2004,104(6):1662-70.
32. Di Virgilio F, et al.Nucleotides receptors: an emerging family of regulatory molecules in blood cells. Blood. 2001; 97:587-600.
33.von Kugelgen I and Wetter A. (2000). Molecular pharmacology of P2Y-receptors.
Naunyn Schmiedebergs Arch Pharmacol 362:310-323.
34.Communi D, et al. (1997). Cloning of a human purinergic P2Y receptor coupled to phospholipase and adenylyl cyclase. J Biol Chem 272:31969-31973.
35.North RA and Surprenant A. (2000). Pharmacology of cloned P2X receptors. Annu Rev Pharmacol Toxicol 40:563-580.
36.Ferrari D, Stroh C, Schulze-Osthoff K. (1999). P2X7/P2Z purinoreceptor-mediated activation of transcription factor NFAT in microglial cells. J Biol Chem 274:13205-13210.
37.Ferrari D, et al. (1997). Extracellular ATP activates transcription factor NF-kappaB through the P2Z purinoreceptor by selectively targeting NF-kappaB p65. J Cell Biol 139:1635-1643
38.Gu BJ, Bendall LJ and Wiley JS. (1998). Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. Blood 3:946-951
39.Wiley JS and Dubyak GR. (1989). Extracellular adenosine triphosphate increases cation permeability of chronic lymphocytic leukemic lymphocytes. Blood 73:1316-1323.
40.Adinolfi E, et al.. (2002).P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood 99:706-708.
41.Coutinho-Silva R, et al.. (2005). P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation. Am J Physiol Gastrointest Liver Physiol 288:G1024-35
42.Slater M, Barden JA. (2005a).Differentiating keratoacanthoma from squamous cell carcinoma by the use of apoptotic and cell adhesion markers. Histopathology 47:170-8.
43.Slater M, et al. (2005b).Expression of the apoptotic calcium channel P2X7 in the glandular epithelium. J Mol Histol. 36:159-65.
44.Raffaghello L, et al. (2006).The P2X7 receptor sustains the growth of human neuroblastoma cells through a substance P-dependent mechanism. Cancer Res 66:907-14.
45.Yamaguchi M, et al. (1994). Enhancement of differentiation induction of mouse myelomonocytic leukemic cells by extracellular ATP. J Cell Physiol 159:441-9.
46.Conigrave AD, et al. (2000).Extracellular ATP-dependent suppression of proliferation and induction of differentiation of human HL-60 leukemia cells by distinct mechanisms. Biochem Pharmacol 60:1585-91
47.Adinolfi E, et al. (2005).Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth.Mol Biol Cell 16:3260-72.
48.Zhang XJ, et al. (2004).Expression of P2X7 in human hematopoietic cell lines and leukemia patients.Leuk Res 28:1313-22.

Parole Chiave

CELLULE STAMINALI LEUCEMICHE, LEUCEMIA ACUTA MIELOIDE, RECETTORI P2, PROFILO DI ESPRESSIONE GENICA, SILENZIAMENTO GENICO, TRAPIANTO XENOGENICO, AGENTI DIFFERENZIANTI, NUCLEOTIDI EXTRACELLULARI